| Year | Title | Publication | Support |
| 2021 | Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells | Cancer Research Communications | Funding, Models |
| Molecular features and vulnerabilities of recurrent chordomas | Journal of Experimental & Clinical Cancer Research | Data, Prize |
| Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma | Scientific Reports | Models |
| Phase 1 open-label trial of intravenous administration of MVA-BN-brachyuryTRICOM vaccine in patients with advanced cancer | Journal for ImmunoTherapy of Cancer | Clinical Trial Support |
| Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma | The Oncologist | Clinical Trial Support |
| Aldehyde Dehydrogenase, a Therapeutic Target in Chordoma: Analysis in 3D Cellular Models | Cells | Models |
| DNA Methylation based prognostic subtypes of chordoma tumors in tissue and plasma | Neuro-Oncology | Funding, Models |
| AZD8055 enhances in vivo efficacy of afatinib in chordomas | Journal of Pathology | Funding, Models |
| Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity | Cell Reports Medicine | Funding, Models |
| 2020 | Defective HLA Class I expression and patterns of lymphocyte infiltration in chordoma tumors | Clinical Orthopaedics and Related Research | Funding |
| The mutational landscape of spinal chordomas and their sensitive detection using circulating tumor DNA | Neuro-Oncology Advances | Funding |
| Inhibition of histone H3K27 demethylases inactivates brachyury (TBXT) and promotes chordoma cell death | Cancer Research | Funding, Models |
| The sacral chordoma margin | European Journal of Surgical Oncology | Authorship |
| Synergistic drug combinations and machine learning for drug repurposing in chordoma | Scientific Reports | Models |
| Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma | Journal of Pathology | Funding, Models |
| Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy | Journal of Neuro-Oncology | Models, Data |
| 2019 | Distinctive role of dysregulated miRNAs in chordoma cancer stem-like cell maintenance | Experimental Cell Research | Models |
| Combination of PARP inhibitor and temozolomide to suppress chordoma progression | Journal of Molecular Medicine | Models |
| Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma | Journal of Medicinal Chemistry | Models |
| Small-molecule targeting of brachyury transcription factor addiction in chordoma | Nature Medicine | Funding, Models, Authorship |
| 2018 | CDK4 expression in chordoma: A potential therapeutic target. | Journal of Orthopaedic Research | Models |
| Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition | Journal for ImmunoTherapy of Cancer | Models |
| Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. | Journal of Neurosurgery | Models |
| Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma | Neuro-oncology | Models |
| Characterization of the endolysosomal system in human chordoma cell lines: is there a role of lysosomes in chemoresistance of this rare bone tumor? | Histochemistry and Cell Biology | Models |
| A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab | Journal of Neurosurgery | Models |
| U-CH17P, -M and -S, a new cell culture system for tumor diversity and progression in chordoma | International Journal of Cancer | Prize |
| Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and Brachyury | Molecular Cancer Therapeutics | Models, Data, Authorship |
| 2017 | Emerging opportunities for target discovery in rare cancers | Cell Chemical Biology | Data |
| The driver landscape of sporadic chordoma | Nature Communications | Funding, Models, Authorship |
| Establishment and genomic characterization of the new chordoma cell line Chor-IN-1 | Scientific Reports | Models, Prize |
| Validation of reference genes in human chordoma | Surgical Neurology International | Funding, Models |
| UM-Chor1: establishment and characterization of first validated clival chordoma cell line | Journal of Neurosurgery | Models, Prize |
| Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group | Annals of Oncology | Funding, Authorship |
| Notochord isolation using laser capture microdissection | Journal of Chemical Neuroanatomy | Funding |
| Integrated and quantitative proteomics of human tumors | Methods of Enzymology | Funding |
| Symptom burden and life challenges reported by adult chordoma patients and their caregivers | Quality of Life | Data, Authorship |
| 2016 | STAT3 inhibition as a therapeutic strategy for chordoma | Journal of Neurological Surgery | Models |
| Establishment of clival chordoma cell line-MUG-CC1 and lymphoblastoid cells as a model for potential new treatment strategies | Scientific Reports | Prize |
| IKK/NF-kB signaling contributes to glioblastoma stem cell maintenance | Oncotarget | Models, Authorship |
| EGFR inhibitors identified as potential treatment for chordoma in a focused compound screen | The Journal of Pathology | Models, Data |
| 2015 | Building a global consensus approach to chordoma: a position paper from the medical and patient community | The Lancet Oncology | Funding, Authorship |
| Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas | Epigenetics | Models |
| Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma | Oncotarget | Models |
| MicroRNA-155 expression is independently predictive of outcome in chordoma | Oncotarget | Funding, Models |
| Phase 1 trial of yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury | Cancer Immunology Research | Clinical Trial Support |
| Preclinical characterization of novel chordoma cell systems and their targeting by pharmacological inhibitors of the CDK4/6 cell-cycle pathway | Cancer Research | Prize |
| Combined PDGFR and HDAC inhibition overcomes PTEN disruption in chordoma | PLoS ONE | Models |
| 2014 | PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment | Journal of Neuro-Oncology | Funding, Models |
| The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival | Carcinogenesis | Models |
| Investigating microenvironmental regulation of human chordoma cell behavior | PLoS ONE | Funding, Models |
| Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma | Journal of Orthopaedic Research | Funding, Models |
| FAS/FASL are dysregulated in chordoma and their loss-of-function impairs zebrafish notochord formation | Oncotarget | Models |
| Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines | Journal of Neurosurgery: Spine | Models |
| Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma | Human Genetics | Funding |
| 2013 | Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies | Neuro-Oncology | Funding |
| Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma | Journal of Neurosurgery | Prize |
| Erlotinib inhibits growth of a patient-derived chordoma xenograft | PLoS ONE | Funding |
| A novel chordoma xenograft allows in vitro drug testing and reveals the importance of NF-kB signaling in chordoma biology | PLoS ONE | Funding |
| MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas | Journal of Neuro-Oncology | Models |
| Identification of repurposed small molecule drugs for chordoma therapy | Cancer Biology & Therapy | Models, Authorship |
| 2012 | An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma | Journal of Pathology | Models |
| A common single-nucleotide variant in T is strongly associated with chordoma | Nature Genetics | Funding |
| Characterization of cancer stem-like cells in chordoma | Journal of Neurosurgery | Models |
| Controlled release of doxorubicin from PH-responsive microgels | Acta Biomaterialia | Models |
| 2011 | The effects of chemotherapeutic agents on differentiated chordoma cells | Journal of Neurosurgery: Spine | Models |
| In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions, and chemotherapeutic drugs | Radiation Oncology | Models |
| Massive genomic rearrangement acquired in a single catastrophic event during cancer development | Cell | Funding |
| Role of transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional based study | Journal of Pathology | Funding, Models |
| 2010 | Molecular characterization of putative chordoma cell lines | Sarcoma | Funding, Authorship |
| Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma | Journal of Pathology | Authorship |
| 2009 | T (brachyury) gene duplication confers major susceptibility to familial chordoma | Nature Genetics | Funding |
| Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas | Clinical Cancer Research | Models |
